Overview

TART - Troglitazone Atherosclerosis Regression Trial

Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Parke-Davis
Treatments:
Troglitazone